GlassScriptPhysician profile
Monica Sok
NPI 1609300409
$3,855.07
in general payments reported to CMS, 2019-2025
35 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $1,055 · 2023: $851 · 2024: $627 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $491.46 | 2021-2025 | Slynd |
| Organon LLC | $438.72 | 2021-2025 | Nexplanon |
| Pfizer INC. | $411.75 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $309.47 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $235.57 | 2022-2025 | Accrufer |
| Abbvie INC. | $225.61 | 2022-2024 | Liletta, Lo Loestrin Fe, Orilissa |
| Gynesonics, INC. | $198.70 | 2021-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Coopersurgical, INC. | $153.00 | 2023-2025 | Mara Console |
| Mayne Pharma Commercial LLC | $148.66 | 2021-2025 | |
| Myriad Women'S Health, INC. | $127.72 | 2023 | Myrisk |
| Millicent US INC | $96.43 | 2023-2025 | Intrarosa, Femlyv |
| Therapeuticsmd, INC. | $79.53 | 2021-2022 | |
| Hologic Sales and Service, LLC | $76.83 | 2023-2024 | Myosure Tissue Removal Device, Acessa Provu System, Coolseal Generator |
| Astellas Pharma US INC | $70.48 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $63.64 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $61.93 | 2023-2025 | Stravix, Stravix Pl |
| Myovant Sciences INC. | $58.42 | 2021-2022 | |
| Heron Therapeutics, INC. | $58.00 | 2022-2023 | Zynrelef |
| Daiichi Sankyo INC. | $56.52 | 2021-2023 | Injectafer |
| Avion Pharmaceuticals | $51.60 | 2021-2023 | Balcoltra |
| Sage Therapeutics, LLC | $44.02 | 2025 | Zurzuvae |
| Dilon Technologies, INC. | $43.96 | 2025 | Hemoblast Bellows |
| Applied Medical Resources Corporation | $42.26 | 2022 | |
| Merck Sharp & Dohme LLC | $37.43 | 2021-2024 | Gardasil 9, Gardasil |
| Exact Sciences Corporation | $35.02 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $34.37 | 2023-2025 | Wegovy, Saxenda |
| Biohaven Pharmaceutical Holding Company LTD. | $34.29 | 2022 | |
| Minerva Surgical, INC | $33.18 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $29.78 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $23.85 | 2022 | |
| Octapharma USA, INC. | $17.29 | 2025 | Fibryga |
| Ethicon US, LLC | $17.09 | 2025 | Stratafix |
| Alexion Pharmaceuticals, INC. | $16.88 | 2022 | |
| Meditrina | $16.64 | 2025 | |
| Medtronic, INC. | $14.97 | 2023 | Ligasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Sok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.